Merkel Cell Carcinoma Concurrent with Bowen's Disease.

Feb 2012

Park HC, Kang HS, Park KT, Oh YH, Yu HJ, Kim JS.

Source

Department of Dermatology, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Korea.

Abstract

Merkel cell carcinoma (MCC) is a rare, aggressive cutaneous malignancy of the elderly and immunocompromised patients. It is occasionally found coexisting with other diseases, such as squamous cell carcinoma, basal cell carcinoma, actinic keratosis, miscellaneous adnexal tumors, and rarely Bowen disease. A 75-year-old woman presented with a 6-month history of an irregularly shaped erythematous patch on the left mandibular angle. Three months later, a 1.5×1.0 cm sized painless and rapidly growing erythematous nodule developed on the patch. Microscopically, the patch lesion was consistent with that of Bowen disease. The nodular lesion showed a number of small uniform hyperchromatic cells with scanty cytoplasm. It showed dense small-cell like nodular infiltration in the dermis. Immunohistochemical staining for cytokeratin 20 showed a positive result with a dot-like perinuclear pattern. Additionally, the result for thyroid transcription factor-1 was negative, which is positive in small cell neuroendocrine carcinoma. From these findings, we diagnosed this lesion as MCC concurrent with Bowen disease.

Annals of Dermatology

Sentinel lymph node biopsy in patients with Merkel cell carcinoma

Sentinel lymph node biopsy in patients with Merkel cell carcinoma: An emerging role and the Westmead hospital experience.

Feb 2012

Howle J, Veness M.

Source

Departments of Surgical Oncology Radiation Oncology, University of Sydney, Westmead Hospital, Sydney, New South Wales, Australia.

Abstract

Background: 

Merkel cell carcinoma (MCC) is an aggressive cutaneous malignancy which has a high rate of nodal metastasis. Sentinel lymph node biopsy (SLNB) enables the identification of occult nodal metastases. We sought to calculate the rates of positive and false negative SLNB and to evaluate the impact of SLNB on the staging and management of patients with MCC at our institution.

Methods: 

A total of 16 patients with stage I or II MCC who had undergone SLNB were identified from a prospectively maintained database of 114 patients with MCC who presented to Westmead Hospital, Sydney, Australia between 2000 and 2010. Data on patient characteristics, tumour and treatment details and patient follow up were extracted from a computer database and patient medical records.

Results: 

Eight patients (50%) had a positive SLNB and eight had a negative SLNB. The median follow up from diagnosis was 19.5 months (range 4-40) with most patients (69%) alive without evidence of disease at the time of last follow up. All eight patients with a positive SLNB subsequently underwent nodal treatment. This consisted of radiotherapy in five and completion lymphadenectomy and adjuvant radiotherapy in three. None of the eight patients who had a negative SLNB underwent any nodal treatment following SLNB. Two of these patients developed nodal relapse, giving a false negative rate of 20%.

Conclusion: 

Half of our patients were upstaged and underwent nodal treatment as a result of their SLNB. Given the high rate of SLNB positivity, we believe that SLNB has a role in the management of MCC. As there is a risk of a false negative SLNB, close observation of the regional nodal basins is warranted in patients who have had a negative SLNB. Further studies are required to investigate the impact of SLNB on survival.

PubMed

Click on the following link for additional information on Sentinel Node Biopsy